Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals has a breakthrough drug for stroke and TBI. The Co. has approximately $2MM in investor commitments to this round.
- Stage Prototype Ready
- Industry Biotechnology
- Location United States
- Currency USD
- Founded January 2005
- Employees 2
- Website remedypharmaceuticals.com
Company Summary
Remedy Pharmaceuticals’ drug, RP-1127, mitigates the damaging after-effects of stroke and traumatic brain injury (TBI). The US & EU market for these indications is estimated at over $4Billion. Many previous attempts to treat stroke and TBI focused on neurons and required the molecule to cross what is called the “Blood Brain Barrier”—and all failed. Remedy’s drug works in a completely different manner— on the capillaries that comprise the
Team
-
Sven JacobsonCEO
Experienced early stage biotech entrepreneur and investor.
Co-founded (as CEO or COO) Remedy Pharmaceuticals, Cure Therapeutics, Critical Diagnostics, Access Scientific, St. Camillus Medical. -
Dr. Eugene MeansMedical Director
Group Director of CNS at Upjohn and Executive Director of CNS and Medical Leader of Emerging Products at Astra Merck / AstraZeneca.
Worked on Tirilizad, Zendra, NXY-059. -
Dr. Marc SimardFounder & Chief Scientific Advisor
Discoverer of the SUR1/TRPM4 channel.
Professor of Neurosurgery, Pathology and Physiology, University of Maryland. Chief of Neurological Service, Baltimore V.A. Medical Center.
Previous Investors
-
Carrot Capital: $4MMUnconfirmedING LLC (Neurosurgeaons): >$700KUnconfirmedDr. Simard: $1MMUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.